Patent 7091174 was granted and assigned to McMaster University on August, 2006 by the United States Patent and Trademark Office.
Novel compound called caloxins which are extracellular plasma membrane (PM) Ca2+-pump inhibitors are described. One caloxin is caloxin 2A1 and has the amino acid sequence VSNSNWPSFPSSGGG. Another caloxin is caloxin 3A1 and has the amino acid sequence DSHINNEPSRRRGGGK. The caloxins are useful in inhibiting PM Ca2+-pumps and can be used in the development of treatments of various diseases including hypertension, hypotension, degenerative brain disorders, mood disorders, diabetes, kidney failure and cancer.